{"id":"hyper-diluted-botox","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or bruising"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle weakness"},{"rate":null,"effect":"Ptosis or eyelid drooping"}]},"_chembl":{"chemblId":"CHEMBL1201574","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, leading to temporary muscle paralysis. A hyper-diluted formulation may allow for broader distribution or different clinical applications while maintaining the same fundamental mechanism of action at reduced toxin concentrations.","oneSentence":"Hyper-diluted botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, potentially at lower concentrations than standard Botox formulations.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:23:15.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational formulation; specific Phase 2 indications not publicly detailed"}]},"trialDetails":[{"nctId":"NCT03097835","phase":"PHASE2","title":"Evaluation of Skin Quality Improvement","status":"COMPLETED","sponsor":"Steve Yoelin M.D. Medical Associates, Inc.","startDate":"2018-02-12","conditions":"Skin Quality","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Hyper-Diluted Botox","genericName":"Hyper-Diluted Botox","companyName":"Steve Yoelin M.D. Medical Associates, Inc.","companyId":"steve-yoelin-m-d-medical-associates-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hyper-diluted botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, potentially at lower concentrations than standard Botox formulations. Used for Investigational formulation; specific Phase 2 indications not publicly detailed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}